Analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to post $4.45 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $11.30 million and the lowest is $500,000.00. Crispr Therapeutics reported sales of $32.33 million in the same quarter last year, which would suggest a negative year over year growth rate of 86.2%. The company is expected to announce its next quarterly earnings results on Thursday, March 14th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $9.10 million for the current year, with estimates ranging from $3.40 million to $23.20 million. For the next financial year, analysts anticipate that the business will post sales of $34.78 million, with estimates ranging from $8.00 million to $91.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Thursday, November 8th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $2.64 million. Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 47.32%. The business’s revenue was down 76.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.62) EPS.
Several equities analysts recently weighed in on the stock. BidaskClub upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 3rd. Chardan Capital restated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Crispr Therapeutics from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a report on Tuesday, October 9th. Wells Fargo & Co started coverage on shares of Crispr Therapeutics in a report on Wednesday, October 10th. They issued an “outperform” rating and a $65.00 price objective on the stock. Finally, Raymond James started coverage on shares of Crispr Therapeutics in a report on Thursday, September 20th. They issued an “underperform” rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $62.47.
Hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. acquired a new position in Crispr Therapeutics in the 2nd quarter worth $116,000. Signaturefd LLC lifted its holdings in Crispr Therapeutics by 123.8% in the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after buying an additional 1,300 shares in the last quarter. First Mercantile Trust Co. acquired a new position in Crispr Therapeutics in the 2nd quarter worth $141,000. SeaCrest Wealth Management LLC lifted its holdings in Crispr Therapeutics by 202.9% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after buying an additional 1,826 shares in the last quarter. Finally, TRUE Private Wealth Advisors acquired a new position in Crispr Therapeutics in the 3rd quarter worth $122,000. Hedge funds and other institutional investors own 39.49% of the company’s stock.
NASDAQ:CRSP opened at $36.37 on Friday. Crispr Therapeutics has a twelve month low of $16.70 and a twelve month high of $73.90.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
See Also: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.